Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules
Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) is a leading clinical stage TechBio company decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously generate one of the world's largest proprietary biological and chemical datasets. Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias. By commanding massive experimental scale — up to millions of wet lab experiments weekly — and massive computational scale — owning and operating one of the most powerful supercomputers in the world, Recursion is uniting technology, biology and chemistry to advance the future of medicine.Salt Lake City, Utah, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. ("Recursion") (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced that on December 19, 2024, the Compensation Committee of Recursion's Board of Directors approved the grant of inducement restricted stock unit (RSU) awards covering 7,952,836 shares of its class A common stock in the aggregate to 230 new employees under Recursion's 2024 Inducement Equity Incentive Plan (the "2024 Plan"). Each award was granted as an inducement material to the employee's commencement of employment with a subsidiary of Recursion in connection with Recursion's acquisition of Exscientia plc and pursuant to Nasdaq Listing Rule 5635(c)(4).
猶他州鹽湖城，2024年12月20日（全球新聞稿）-- Recursion Pharmaceuticals, Inc.（「Recursion」）（納斯達克：RXRX），是一家領先的臨牀階段科技生物公司，致力於解碼生物學以工業化藥物發現，今天宣佈在2024年12月19日，Recursion的董事會薪酬委員會批准授予230名新員工的誘導限制股票單位（RSU）獎勵，總計覆蓋7,952,836股其A級普通股，依據Recursion的2024年誘導股權激勵計劃（「2024計劃」）。每項獎勵的授予與員工加入Recursion的子公司有關，並且是Recursion收購Exscientia plc的誘導條件，同時根據納斯達克上市規則5635(c)(4)進行。
Each inducement RSU award will vest as to 1/16th of the shares subject to the award quarterly on each of February 15, May 15, August 15, and November 15, beginning with February 15, 2025 until the inducement RSU award is fully vested, subject to the inducement RSU award recipient's continued employment through the Company Vesting Dates. Each inducement RSU award is subject to the terms and conditions of the 2024 Plan and the grant agreements covering the awards.
每項誘導RSU獎勵將在2025年2月15日開始，每季度按份額的1/16歸屬，直到誘導RSU獎勵完全歸屬，前提是誘導RSU獎勵接收人在公司歸屬日期仍在職。每項誘導RSU獎勵均遵循2024計劃的條款和條件以及涵蓋這些獎勵的授予協議。
About Recursion Pharmaceuticals
關於Recursion Pharmaceuticals
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) is a leading clinical stage TechBio company decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously generate one of the world's largest proprietary biological and chemical datasets. Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias. By commanding massive experimental scale — up to millions of wet lab experiments weekly — and massive computational scale — owning and operating one of the most powerful supercomputers in the world, Recursion is uniting technology, biology and chemistry to advance the future of medicine.
Recursion Pharmaceuticals, Inc.（納斯達克：RXRX）是一家領先的臨牀階段科技生物公司，致力於解碼生物學以工業化藥物發現。推動其使命的是Recursion OS，這是一個建立在多種技術基礎上的平台，持續生成全球最大的專有生物和化學數據集之一。Recursion利用複雜的機器學習算法，從其數據集中提煉出數萬億個可搜索的生物學和化學關係，超越人爲偏見。通過指揮大規模實驗——每週進行多達數百萬個溼實驗——以及大規模計算——擁有並運營全球最強大的超級計算機之一，Recursion將科技、生物學和化學結合在一起，以推動醫學的未來。
Recursion is headquartered in Salt Lake City, where it is a founding member of BioHive, the Utah life sciences industry collective. Recursion also has offices in Toronto, Montréal, New York, London, Oxford area, and the San Francisco Bay area. Learn more at , or connect on X (formerly Twitter) and LinkedIn.
Recursion總部位於鹽湖城，是猶他州生命科學行業集體BioHive的創始成員。Recursion在多倫多、蒙特利爾、紐約、倫敦、牛津地區以及舊金山灣區也設有辦公室。了解更多信息，請訪問，或在X（前Twitter）和LinkedIn上聯繫。
Media Contact
Media@Recursion.com
媒體聯繫
Media@Recursion.com
Investor Contact
Investor@Recursion.com
投資者聯繫
Investor@Recursion.com
CONTACT: Ryan Kelly
Recursion Pharmaceuticals
media@recursion.com
聯繫人：瑞安·凱利
Recursion Pharmaceuticals
media@recursion.com
譯文內容由第三人軟體翻譯。
